7 results on '"Xue, Huiru"'
Search Results
2. Pain in neuromyelitis optic spectrum disorder
- Author
-
Xue, Huiru, Yang, Wen, Zhao, Yunfei, Wang, Li, Wang, Guilian, Zhang, Meini, and Zhang, Hui
- Published
- 2022
- Full Text
- View/download PDF
3. Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China.
- Author
-
Guo, Jun, Wu, Jiayong, Wang, Lihua, Liu, Hongbo, Wu, Xiaomu, Yang, Huan, Li, Wenyu, Wang, Honghao, Bu, Bitao, Yang, Chunsheng, Zhou, Hongyu, Guo, Shougang, Zhao, Yinan, Wang, Zhanhang, Li, Chunyang, Tian, De-Cai, Chen, Sheng, Xue, Huiru, Zhang, Yanlin, and Xu, Yongfeng
- Subjects
MULTIPLE sclerosis treatment ,DISEASE relapse ,DISEASE prevalence ,CORTICOSTEROIDS ,MEDICAL protocols - Abstract
Multiple sclerosis (MS) was defined as a rare disease in China due to its low prevalence. For a long time, interferon β was the only approved disease-modifying therapy (DMT). Since the first oral DMT was approved in 2018, DMT approval accelerated, and seven DMTs were approved within 5 years. With an increasing number of DMTs being prescribed in clinical practice, it is necessary to discuss the standardized MS treatment algorithms depending on the disease activity and DMT availability. In this review paper, more than 20 Chinese experts in MS have reviewed the therapeutic progress of MS in China and worldwide and discussed algorithms for treating relapsing MS (RMS) based on the available DMTs in China, providing insights for establishing the standardized RMS treatment algorithms in this country. Plain language summary: Treatment algorithms of relapsing multiple sclerosis in China In this review paper, more than 20 Chinese experts in MS have reviewed the therapeutic progress of MS in China and worldwide and discussed algorithms for treating relapsing MS (RMS) based on the available DMTs in China, providing insights for establishing the standardized RMS treatment algorithms in this country: 1) CIS and RRMS account for more than 90% of the MS patients and most of them are mild to moderate; 2) MS patients should initiate DMT treatments as soon as the disease has been diagnosed in order to reduce the risk of disease progression; 3) Patients who have been diagnosed with MS should start treatment with fundamental DMTs unless the disease course has been highly active; 4) MAGNIMS score may be a suitable and simplified assessment tool for measuring treatment response to DMTs; 5) Patients treated with corticosteroids and NSIS should be switched to the standardized DMT treatment during remission in accordance with disease activity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study
- Author
-
Zhang, Meini, Zhang, Chuntao, Bai, Peng, Xue, Huiru, and Wang, Guilian
- Published
- 2017
- Full Text
- View/download PDF
5. Factors Influencing the Degree of Disability in Patients With Multiple Sclerosis.
- Author
-
Xue, Huiru, Yang, Zhenzhen, Wang, Li, Jiang, Yayun, Li, Jiayang, Wu, Minghui, Wang, Guilian, Zhang, Yuanyuan, and Zhang, Meini
- Subjects
MULTIPLE sclerosis ,DISABILITIES ,DRUG utilization ,LOGISTIC regression analysis ,RECEIVER operating characteristic curves ,PEOPLE with disabilities ,CHILDREN with disabilities ,CRANIOCEREBRAL injuries - Abstract
Objective: To explore the factors influencing the degree of disability in patients with multiple sclerosis (MS), and to provide evidence for its early diagnosis, prognostic evaluation and clinical intervention. Methods: This retrospective observational study included 72 patients with relapsing-remitting multiple sclerosis (RRMS) at the First Hospital of Shanxi Medical University. All patients completed craniocerebral and spinal cord MRI (with or without Gd enhancement) and were evaluated for Expanded Disability Status Score (EDSS) scores before receiving treatment. Results: Among 72 patients with RRMS, 45 (62.5%) had an EDSS score ≤3; A total of 27 patients (37.5%) had an EDSS score >3 points. Univariate analysis showed that age, annual recurrence rate (ARR), drug use, albumin (ALB), triglycerides (TG), and total number of lesions in groups with EDSS score ≤3 were significantly different from those with an EDSS score > 3 points (P < 0.05). Multivariate logistic regression analysis showed that ALB, total number of lesions, and drug use were independent influencing factors of the degree of disability in patients with MS, and the difference was statistically significant (P < 0.05). An ROC curve was constructed using ALB and the total number of lesions. The AUC of ALB was 0.681, P < 0.05, and the best cut-off value was 44.2 g/L. Its sensitivity to predict the degree of disability in patients with multiple sclerosis was 85.2%, while its specificity was 51.1%. The AUC of the total number of lesions was 0.665 (P < 0.05) and the best cut-off value was 5.5. Its sensitivity to predict the degree of disability in patients with multiple sclerosis was 70.4%, while its specificity was 64.4%. The AUC of the combined ALB, total number of lesions, and drug use was 0.795 (P < 0.05), sensitivity was 77.8, and specificity was 73.3%. The optimal diagnostic cut-off value of the regression equation for the EDSS score of patients with multiple sclerosis was 0.420. Conclusion: Serum ALB, total number of lesions, and drug use in patients with multiple sclerosis were independent factors influencing the degree of disability. These findings provide clinical evidence for the prognostic evaluation and early intervention of patients with multiple sclerosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Differential efficacy of mycophenolate mofetil in adults with relapsing myelin oligodendrocyte glycoprotein antibody-associated disorders.
- Author
-
Wang, Meisheng, Zeng, Pei, Du, Chen, Xue, Huiru, Cui, Zhigang, Zhang, Huiming, Jia, Dongmei, and Zhang, Chao
- Abstract
• High-dose mycophenolate mofetil significantly reduced the risk of relapses of MOGAD. • ARR was not decreased on treatment of low-dose mycophenolate mofetil. • The efficacy of mycophenolate mofetil in MOGAD may be dose-dependent. Myelin oligodendrocyte glycoprotein-immunoglobulin (MOG-IgG) associated disorder (MOGAD) has been recognized as a distinct disease entity with recurrent attacks. But the standard therapeutic approach to reduce relapses is unknown. Different doses of mycophenolate mofetil (MMF) are frequently used in MOGAD. We aimed to investigate the response to stratified doses of MMF in adult patients with MOGAD. We determined the frequency of relapses in patients receiving various doses of MMF treatment for MOGAD. Patients were reviewed for relapses before and during long-term treatment. Cox proportional hazards models were used to analyze the correlation between the MMF dosage and the annualized relapse rate (ARR) as well as clinical features. 22 patients receiving low-dose MMF (< 1000 mg/day), 19 patients receiving moderate-dose MMF (1000 mg/day ≤ MMF dose < 2000 mg/day) and 21 patients receiving high-dose MMF (≥ 2000 mg/day) were collected in our cohort. Cox regression analysis showed that high-dose MMF treatment significantly reduced the risk of relapses (HR 0.501 [95% CI 0.268–0.934], p = 0.030) compared with low-dose and moderate-dose of MMF treatment, after adjusted by age, gender, disease duration and prednisone therapy. Patients (13/62) concomitant with autoimmune diseases, had a higher proportion of relapses (76.92%) compared with those without autoimmune diseases (18.37%) (HR = 5.96, 95% CI 1.73–20.48, p < 0.001). The overall median ARR reduced from 1.13 to 0.32 under high-dose MMF treatment (p = 0.004). However, there was no significant reduction in ARR either in patients with low-dose or those with moderate-dose of MMF. This study suggests that high-dose of MMF treatment may reduce recurrent demyelinating attacks, with the lowest ARR. Randomized controlled studies are required to validate the effective therapeutic regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
- Author
-
Li, Huining, Huang, Zhenning, Jia, Dongmei, Xue, Huiru, Pan, Jing, Zhang, Meini, Shi, Kaibin, Shi, Fu-Dong, and Zhang, Chao
- Subjects
- *
MYASTHENIA gravis , *RITUXIMAB , *B cells , *CHOLINERGIC receptors , *CORTICOSTEROIDS , *IMMUNOSUPPRESSIVE agents - Abstract
The aim of this retrospective case series study was to evaluate the response and durability of rituximab in patients with new-onset acetylcholine receptor positive (AChR +) generalized myasthenia gravis (MG). Patients were initiated with low-dose rituximab treatment within 3.5 months of onset without concomitant oral immunosuppressants. Seventeen patients (89%) remained relapse-free with a mean follow-up of 51.3 months. Clinical improvement was observed in parallel with the maintenance of low-dose corticosteroids or the complete discontinuation of corticosteroids. Long-term depletion of B cells with low-dose rituximab treatment has shown favorable efficacy and tolerance in reducing disease activity for AChR+ generalized MG. [Display omitted] • Early initiation of rituximab was used in new-onset AChR+ generalized MG. • Low-dose rituximab regimen was dictated by circulating B cell percentage. • Clinical improvement and tolerance were sustained from long-term B cell depletion. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.